Immuron Ltd (IMRN), Wednesday announced that it has entered into an exclusive agreement with Calmino group AB to launch ProIBS, a certified medical device for the treatment of irritable bowel syndrome symptoms, in Australia and New Zealand.
Following the agreement, ProIBS will join Immuron's product portfolio which includes the Travelan brand.
ProIBS contains AVH200, which has gel forming components that support the intestinal mucosal barrier. A usability study conducted among 1,003 users found that ProIBS is helpful for 94 percent of them.
Tuesday, Immuron's stock closed at $1.75, down 0.79 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.